Verseau Therapeutics

Verseau Therapeutics

Edit info

  • Founded: 2017
  • Location: Bedford, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: VTX-0811
  • Funding: $50M Oct 2019


verseautx.com

linkedin.com


Drug notes:

VTX-1218 RD oncology; 4+ undisclosed programs RD oncology

About:

Verseau Therapeutics aims to develop a new class of immunotherapy treatments for cancer. Their scientific approach centers on repolarizing immune cells, macrophages, from an immuno-suppressive to a pro-inflammatory state. Polarizing macrophages to this state allows them to kill the cancer cells and activate other immune cells within the tumor microenvironment. They have identified and validated numerous targets that can regulate macrophages. Using human cells from patient-derived human tumors, they can determine mechanism of action and preclinical proof of concept for their candidates. Verseau Therapeutics’ cutting-edge technologies, deep biological understanding, and extensive cancer patient genomic data will help them in creating transformative immunotherapies.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com